Related Experiment Video
Updated: Jul 7, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Advances in understanding L-DOPA-induced dyskinesia
1Basal Ganglia Pathophysiology Unit, Department of Experimental Medical Science, Lund University, S-221 84 Lund, Sweden. Angela.Cenci_Nilsson@med.lu.se
Current Opinion in Neurobiology
|March 1, 2008
Summary
Parkinson's disease treatment with L-DOPA can cause abnormal involuntary movements (dyskinesia). Rodent models reveal this is due to altered L-DOPA processing and dopamine receptor overactivity.
Area of Science:
- Neuroscience
- Movement Disorders
- Pharmacology
Background:
- Dopamine (DA) is critical for motor control; its deficiency causes Parkinson's disease (PD) symptoms like slowness of movement.
- L-DOPA effectively treats PD but often induces L-DOPA-induced dyskinesia (LID), a significant side effect characterized by abnormal involuntary movements.
Purpose of the Study:
- To review recent rodent model studies investigating the neurobiological underpinnings of L-DOPA-induced dyskinesia.
- To elucidate the mechanisms behind abnormal pre-synaptic L-DOPA handling and hyper-reactive post-synaptic dopamine responses in LID.
Main Methods:
- Review of recent scientific literature focusing on rodent models of Parkinson's disease and L-DOPA treatment.
- Analysis of studies examining pre-synaptic and post-synaptic alterations in dopaminergic pathways.
Main Results:
- Rodent models show LID is associated with abnormal pre-synaptic handling of L-DOPA and heightened post-synaptic dopamine receptor sensitivity.
- Dysregulation of nigrostriatal dopamine transmission leads to secondary changes in non-dopaminergic systems, influencing dyskinesia.
Conclusions:
- Understanding LID mechanisms requires investigating both pre- and post-synaptic dopamine system alterations.
- Further research into LID will enhance comprehension of neurotransmitter interactions within the basal ganglia motor circuits.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...